GURUFOCUS.COM » STOCK LIST » USA » NAS » Moderna Inc (NAS:MRNA) » Definitions » EV-to-EBIT
Switch to:

Moderna EV-to-EBIT

: 3.83 (As of Today)
View and export this data going back to 2018. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Moderna's Enterprise Value is $60,056 Mil. Moderna's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $15,686 Mil. Therefore, Moderna's EV-to-EBIT for today is 3.83.

The historical rank and industry rank for Moderna's EV-to-EBIT or its related term are showing as below:

MRNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -93.17   Med: -8.58   Max: 110.51
Current: 3.82

During the past 6 years, the highest EV-to-EBIT of Moderna was 110.51. The lowest was -93.17. And the median was -8.58.

MRNA's EV-to-EBIT is ranked better than
55.65% of 478 companies
in the Biotechnology industry
Industry Median: 7.30 vs MRNA: 3.82

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Moderna's Enterprise Value for the quarter that ended in Jun. 2022 was $48,987 Mil. Moderna's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $15,686 Mil. Moderna's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was 32.02%.


Moderna EV-to-EBIT Historical Data

The historical data trend for Moderna's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBIT
Premium Member Only - -9.26 -10.28 -50.80 6.96

Moderna Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.77 19.36 6.96 3.67 3.12

Competitive Comparison

For the Biotechnology subindustry, Moderna's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Moderna EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Moderna's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Moderna's EV-to-EBIT falls into.



Moderna EV-to-EBIT Calculation

Moderna's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=60056.272/15686
=3.83

Moderna's current Enterprise Value is $60,056 Mil.
Moderna's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $15,686 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna  (NAS:MRNA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Moderna's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2022 ) =EBIT / Enterprise Value (Q: Jun. 2022 )
=15686/48987.2
=32.02 %

Moderna's Enterprise Value for the quarter that ended in Jun. 2022 was $48,987 Mil.
Moderna's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $15,686 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Moderna's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Moderna logo
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Gomez Jorge M officer: See Remarks C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277
Burton Paul officer: Chief Medical Officer 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Klinger Shannon Thyme officer: Chief Legal Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Tallett Elizabeth E director 6705 ROCKLEDGE DR SUITE 900 BETHESDA MD 20817
Meline David W officer: Chief Financial Officer 3M COMPANY 3M OFFICE OF GENERAL COUNSEL ST PAUL MN 55144-1000
Horning Sandra director 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Nader Francois director 550 HILLS DRIVE BEDMINSTER NJ 07921
Flagship Venturelabs Iv, Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143
Sagan Paul director AKAMAI TECHNOLOGIES INC 8 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Ruiz Israel director C/O FORTIVE CORPORATION 6920 SEAWAY BOULEVARD EVERETT WA 98203
Zaks Tal Zvi officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Nabel Elizabeth G director BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS ST BOSTON MA 02115
Hoge Stephen officer: President C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Henderson Lori M. officer: General Counsel and Secretary MOLDFLOW CORP 430 BOSTON POST ROAD WAYLAND MA 01778

Moderna Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)